ADAG Adagene ADS (N Shares)

Adagene to Participate in the Jefferies Virtual China Biotech Summit

Adagene to Participate in the Jefferies Virtual China Biotech Summit

SAN FRANCISCO and SUZHOU, China, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual China Biotech Summit to be held October 26, 2021.

Details on the presentation include:

Date: Tuesday, October 26, 2021

Presentation Time: 3:00 p.m. Eastern

A live webcast of the presentation will also be accessible in the section of the company’s website at . A webcast replay will be available for at least 30 days.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody™, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: .

Internal Contact:

Ami Knoefler

Adagene

650-739-9952

External Contact:

Bruce Mackle

LifeSci Advisors

646-889-1200



EN
21/10/2021

Underlying

ADAGAdagene ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adagene ADS (N Shares)

 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Announces First Patient Dosed in Randomized Dose Optimization ...

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on  Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug...

October 31, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Expands SAFEbody® Collaboration and License Agreement with Exe...

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 . Under the terms of the amended agreement, Exelixis will utilize Adagene’s SAFEbody technology platform to generate a masked monoclonal antibody from the company’s pipeline for the development of an antibody-drug conjugate (ADC) against an Exelixis-nominated solid tumor target. Adagene is eligible to receive developm...

September 16, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Ch...

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this year’s CSCO Meeting, taking place September 10-14 in Jinan, China. Harnessing the Power of Masked CTLA-4 Blockade: Updated ADG126-P001 Phase 1b/2Results of ADG126 +...

September 5, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as E...

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. “Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG12...

September 3, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene to Participate in Two Investor Conferences in September

Adagene to Participate in Two Investor Conferences in September SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at two investor conferences in September, both taking place in New York, New York. H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat Date: Monday, September 8F...

August 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch